HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial.

AbstractBACKGROUND:
Control of epigenetic changes using histone deacetylase inhibitors (HDACi) is thought to be a promising target in therapy of gastrointestinal (GI) cancer. In this study, we evaluated the safety, pharmacokinetics, and efficacy of two dosing regimens of vorinostat, an oral HDACi, in patients with GI tumors.
METHODS:
Patients received either vorinostat 300 mg bid for 3 consecutive days followed by 4 rest days per cycle (n = 10) or vorinostat 400 mg qd for 21 consecutive days per cycle (n = 6). Pharmacokinetic parameters were assessed for the first treatment cycle. Efficacy was determined through evaluation of tumors and assessment of treatment response.
RESULTS:
The median treatment duration of 300 mg bid was 52.0 days and of 400 mg qd was 51.5 days. The most common drug-related adverse events were anorexia, nausea, fatigue, and hyperglycemia. Two patients taking 400 mg qd had dose-limiting toxicities (DLTs) of thrombocytopenia. No patients taking 300 mg bid experienced DLT. Five patients taking 300 mg bid and 2 patients taking 400 mg qd maintained stable disease for >8 weeks, with the maximum duration of 245 days. Mean drug exposure (±SD) was generally higher with 400 mg qd (area under the curve [AUC(0-∞)] of 7.75 ± 2.79 μM h on Day 1 post-dose) compared with 300 mg bid (AUC(0-∞) of 3.94 ± 1.56 μM h on Day 1 post-dose).
CONCLUSIONS:
Vorinostat 300 mg bid for 3 consecutive days followed by 4 days of rest was better tolerated in patients with GI cancer than a higher once daily dose. Additionally, there were patients in both groups who achieved stable disease, most maintaining it for longer than 8 weeks, suggesting vorinostat as a possible active agent in the treatment of GI cancer.
AuthorsToshihiko Doi, Tetsuya Hamaguchi, Kuniaki Shirao, Kensho Chin, Kiyohiko Hatake, Kazuo Noguchi, Tetsuya Otsuki, Anish Mehta, Atsushi Ohtsu
JournalInternational journal of clinical oncology (Int J Clin Oncol) Vol. 18 Issue 1 Pg. 87-95 (Feb 2013) ISSN: 1437-7772 [Electronic] Japan
PMID22234637 (Publication Type: Clinical Trial, Phase I, Journal Article)
Chemical References
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • Vorinostat
Topics
  • Aged
  • Dose-Response Relationship, Drug
  • Drug-Related Side Effects and Adverse Reactions (chemically induced)
  • Female
  • Gastrointestinal Neoplasms (blood, drug therapy, pathology)
  • Histone Deacetylase Inhibitors (administration & dosage, adverse effects, blood, pharmacokinetics)
  • Humans
  • Hydroxamic Acids (administration & dosage, adverse effects, blood, pharmacokinetics)
  • Male
  • Maximum Tolerated Dose
  • Middle Aged
  • Neoplasm Staging
  • Vorinostat

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: